All News
Filter News
Found 320 articles
-
The two companies were able to get their antibody candidate into the clinic within two months of announcing their collaboration in response to the global pandemic.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
-
AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment
6/1/2020
AbCellera today announced that LY-CoV555, the lead antibody from the collaboration between AbCellera and Eli Lilly and Company (Lilly), has entered into human testing for the potential treatment of COVID-19.
-
NYU Langone Among First to Enroll Patients In Clinical Trial for COVID-19 Monoclonal Antibody Treatment
6/1/2020
The first patients were treated as part of a clinical trial testing whether an antibody therapy can safely reduce COVID-19 disease severity. T
-
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
6/1/2020
First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera
-
BioSpace Global Roundup, May 28
5/28/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
As part of the scale-up, it plans to hire up to 100 new staffers, bringing total headcount to about 240.
-
AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform
5/27/2020
AbCellera provides pharma and biotech partners with an AI-powered, full-stack drug discovery platform to accelerate development of biologics
-
AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly
5/22/2020
AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets.
-
Minister Bains announces investment in antibody discovery technology to help treat COVID-19
5/3/2020
Government of Canada supports innovative project to combat COVID-19 and build Canadian capabilities to fight future pandemics
-
With the trillions of antibodies the human body can make, finding the antibody with the right combination of potency against a target and ease of manufacturing is, at best, an arduous, time-intensive endeavor for drug developers. AbCellera Biologics has developed a way to dramatically speed that ...
-
Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance
4/23/2020
Revenue in the first quarter of 2020 increased 15 percent, driven by 22 percent volume growth. Strong underlying demand for key growth products was augmented by approximately $250 million of additional revenue due to increased customer buying patterns and patient prescription trends due to the COVID-19 pandemic.
-
Eli Lilly will begin exploring the use of its rheumatoid arthritis drug Olumiant as a treatment for hospitalized patients with COVID-19. A clinical trial will begin this month and results are expected within the next two months.
-
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...
-
The U.S. Food and Drug Administration granted Eli Lilly and Company and Incyte Corporation Breakthrough Therapy designation for baricitinib for alopecia areata.
-
Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution.
-
Canada’s Medicago announced Thursday it has successfully produced a Virus-Like Particle of the coronavirus just 20 days after obtaining the SARS-CoV-2 gene. The company is now focused on developing a vaccine for COVID-19, the virus caused by SARS-CoV-2.
-
AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19
3/12/2020
AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID-19 [12-March-2020] VANCOUVER, British Columbia and INDIANAPOLIS , March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they
-
INSERTING and REPLACING AbCellera Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020
3/10/2020
AbCellera, the antibody company, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2020 for its drug discovery platform that can search and analyze natural immune systems to deliver best-in-class antibody drugs.
-
AbCellera Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020
3/10/2020
AbCellera, the antibody company, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2020 for its drug discovery platform that can search and analyze natural immune systems to deliver best-in-class antibody drugs.